首页 | 本学科首页   官方微博 | 高级检索  
     

沙立度胺联合VAD方案治疗初发多发性骨髓瘤疗效观察
引用本文:刘蕴华. 沙立度胺联合VAD方案治疗初发多发性骨髓瘤疗效观察[J]. 中国实用医药, 2011, 6(27): 42-43
作者姓名:刘蕴华
作者单位:河南省信阳市中心医院血液科,464000
摘    要:目的观察沙立度胺联合VAD方案治疗初发多发性骨髓瘤(MM)患者的临床疗效和不良反应。方法选择35例初发多发性骨髓瘤患者,采用沙立度胺联合VAD方案进行化疗,每一个疗程为21d,每个疗程之后间歇4周,治疗3个疗程后观察临床疗效及药物的毒副反应。结果治疗3个疗程后,5例患者完全缓解,19例患者部分缓解,进步5例、总有效率为82.8%。毒副反应为骨髓抑制,指端麻木及便秘等。结论沙立度胺联合VAD方案治疗初发MM患者疗效较好,不良反应可以耐受,值得临床推广。

关 键 词:沙立度胺  VAD方案  多发性骨髓瘤

Clinical efficacy of Thalidomide combined VAD regimen in the treatment multiple myeloma
LIU Yun-hua. Clinical efficacy of Thalidomide combined VAD regimen in the treatment multiple myeloma[J]. China Practical Medical, 2011, 6(27): 42-43
Authors:LIU Yun-hua
Affiliation:LIU Yun-hua.Department of Hematology,The Central Hospital of Xinyang City of Henan,Xinyang 464000,China
Abstract:Objective To observe the clinical curative effect and toxicity of drugs of Thalidomide combined VAD regimen on treating newly diagnosed multiple myeloma (MM) patients.Methods 35 patients with newly diagnosed MM treated with Thalidomide combined VAD regimen.Every 21 days a course of treatment,intermittent 4 weeks after treatment,observation of efficacy and toxicity of drugs.Results After treatment for 3 treatments,among the 35 patients,5 patients achieved complete remission(CR)and 19 partial remission(PR),5 ...
Keywords:Thalidomide  VAD regimen  Multiple myeloma  
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号